FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3004296966> ?p ?o ?g. }

• W3004296966 abstract "Neuroblastoma (NB) is one of the most common childhood cancers, constituting 8% of paediatric cancers, and 15% of paediatric cancer deaths. The majority of patients have high risk disease, with poor outcome despite intensive treatment regimens. Current therapies, which include chemotherapy and radiotherapy, are highly toxic, with significant treatment related mortality, and there is little scope for further intensification. Alternatives strategies, such as immunotherapy are a priority for improving patient outcomes. A number of different immunotherapies, such as antiGD2 antibody therapy, have shown promise in NB, but combining these with conventional chemotherapy regimens is challenging. Classically, chemotherapy has been regarded as immunosuppressive but recent work has highlighted that this may not entirely be accurate for certain immunogenic chemotherapies. Furthermore, immunomodulatory antibodies such as checkpoint inhibitors have shown efficacy in adult cancers such as melanoma, with little investigation into their potency in paediatric tumours. Although NB tumours are not particularly inherently immunogenic, the application of an ‘immunogenic’ chemotherapy may render them susceptible to further immunomodulatory immunotherapy. Firstly this study aimed to identify the immunomodulating effects of cyclophosphamide (CPM) treatment on immune cells, within murine NB models. To achieve this, CPM’s ability to induce ‘immunogenic cell death’ (ICD) markers both in vitro and in vivo was investigated. Induction of ectoCRT, Hsp-70 and HMGB1 expression was observed. Secondly, effects of different doses of CPM on the immune cell infiltrates in the tumour microenvironment were studied in vivo using syngeneic murine NB models. It was demonstrated that low dose CPM was able to selectively deplete and possibly reduce the suppressive activity tumour infiltrating Treg cells in both NXS2 and 9464D NB models, alongside maintaining and activating CD8+ and CD4+ T cells. Additionally, using an apoptosis resistant NB cell line and mouse strain, investigation into whether ICD induction or Treg depletion is most critical aspect of CPM immunomodulation was conducted. It was observed that overexpression of BCL-2 either in the tumour cell line in vitro or Treg cells in vivo, prevented apoptosis and CPM dependent depletion. Finally, it was assessed whether immunogenic CPM could be efficiently combined with immunomodulatory antibody therapy to slow tumour growth, utilising a combination of syngeneic and spontaneous transgenic NB models. Experiments utilising the three in vivo models demonstrated that combination of CPM with anti-PD-1 antibody led to an increase in survival over monotherapies alone, which was further enhanced by a metronomic weekly dosing strategy. Ongoing work is exploring this approach, to refine and establish the most effective chemotherapy and antibody combination in NB preclinical models, along with defining the mechanisms behind combination efficacy." @default.
• W3004296966 created "2020-02-07" @default.
• W3004296966 creator A5025779501 @default.
• W3004296966 date "2018-12-01" @default.
• W3004296966 modified "2023-09-27" @default.
• W3004296966 title "Combination of immunodoulatory cyclophosphamide with anti-PD-1 monoclonal antibody therapy to improve survival in preclinical models of neuroblastoma" @default.
• W3004296966 hasPublicationYear "2018" @default.
• W3004296966 type Work @default.
• W3004296966 sameAs 3004296966 @default.
• W3004296966 citedByCount "0" @default.
• W3004296966 crossrefType "dissertation" @default.
• W3004296966 hasAuthorship W3004296966A5025779501 @default.
• W3004296966 hasConcept C121608353 @default.
• W3004296966 hasConcept C126322002 @default.
• W3004296966 hasConcept C143998085 @default.
• W3004296966 hasConcept C150903083 @default.
• W3004296966 hasConcept C159654299 @default.
• W3004296966 hasConcept C203014093 @default.
• W3004296966 hasConcept C207001950 @default.
• W3004296966 hasConcept C2776107976 @default.
• W3004296966 hasConcept C2776694085 @default.
• W3004296966 hasConcept C2776715637 @default.
• W3004296966 hasConcept C2776755627 @default.
• W3004296966 hasConcept C2777701055 @default.
• W3004296966 hasConcept C2777877232 @default.
• W3004296966 hasConcept C502942594 @default.
• W3004296966 hasConcept C509974204 @default.
• W3004296966 hasConcept C542903549 @default.
• W3004296966 hasConcept C54355233 @default.
• W3004296966 hasConcept C71924100 @default.
• W3004296966 hasConcept C81885089 @default.
• W3004296966 hasConcept C86803240 @default.
• W3004296966 hasConcept C8891405 @default.
• W3004296966 hasConceptScore W3004296966C121608353 @default.
• W3004296966 hasConceptScore W3004296966C126322002 @default.
• W3004296966 hasConceptScore W3004296966C143998085 @default.
• W3004296966 hasConceptScore W3004296966C150903083 @default.
• W3004296966 hasConceptScore W3004296966C159654299 @default.
• W3004296966 hasConceptScore W3004296966C203014093 @default.
• W3004296966 hasConceptScore W3004296966C207001950 @default.
• W3004296966 hasConceptScore W3004296966C2776107976 @default.
• W3004296966 hasConceptScore W3004296966C2776694085 @default.
• W3004296966 hasConceptScore W3004296966C2776715637 @default.
• W3004296966 hasConceptScore W3004296966C2776755627 @default.
• W3004296966 hasConceptScore W3004296966C2777701055 @default.
• W3004296966 hasConceptScore W3004296966C2777877232 @default.
• W3004296966 hasConceptScore W3004296966C502942594 @default.
• W3004296966 hasConceptScore W3004296966C509974204 @default.
• W3004296966 hasConceptScore W3004296966C542903549 @default.
• W3004296966 hasConceptScore W3004296966C54355233 @default.
• W3004296966 hasConceptScore W3004296966C71924100 @default.
• W3004296966 hasConceptScore W3004296966C81885089 @default.
• W3004296966 hasConceptScore W3004296966C86803240 @default.
• W3004296966 hasConceptScore W3004296966C8891405 @default.
• W3004296966 hasLocation W30042969661 @default.
• W3004296966 hasOpenAccess W3004296966 @default.
• W3004296966 hasPrimaryLocation W30042969661 @default.
• W3004296966 hasRelatedWork W1537537127 @default.
• W3004296966 hasRelatedWork W1991838289 @default.
• W3004296966 hasRelatedWork W2013248985 @default.
• W3004296966 hasRelatedWork W2103707167 @default.
• W3004296966 hasRelatedWork W2595067628 @default.
• W3004296966 hasRelatedWork W2735939614 @default.
• W3004296966 hasRelatedWork W2790541566 @default.
• W3004296966 hasRelatedWork W2810177579 @default.
• W3004296966 hasRelatedWork W2810770949 @default.
• W3004296966 hasRelatedWork W287605918 @default.
• W3004296966 hasRelatedWork W2895515586 @default.
• W3004296966 hasRelatedWork W2901755476 @default.
• W3004296966 hasRelatedWork W3043229005 @default.
• W3004296966 hasRelatedWork W3090036675 @default.
• W3004296966 hasRelatedWork W3096739463 @default.
• W3004296966 hasRelatedWork W3149397781 @default.
• W3004296966 hasRelatedWork W3164352656 @default.
• W3004296966 hasRelatedWork W3195507259 @default.
• W3004296966 hasRelatedWork W3206042326 @default.
• W3004296966 hasRelatedWork W77405594 @default.
• W3004296966 isParatext "false" @default.
• W3004296966 isRetracted "false" @default.
• W3004296966 magId "3004296966" @default.
• W3004296966 workType "dissertation" @default.